Clinical Trials Logo
  1. Home
  2. HIV Infections
  3. NCT05021653
  4. Details
NCT05021653 Clinical Trial

HIV Resilience Qualitative Study Hong Kong

HIV Infections Clinical Trial

Official title:
Exploration of the Role of Resilience and Its Development in Later Life Among HIV Infected Older Adults: a Qualitative Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05021653
Other study ID # HKHIV resilience 01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2021
Est. completion date June 10, 2023

Study information
Verified date June 2023
Source Chinese University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This qualitative study aims to explore lived experiences of older adults living with HIV in Hong Kong. Twenty older Chinese adults of age 50 or above will be recruited from an HIV specialist clinic providing HIV care in the public service. Qualitative, semi-structured interview will be conducted to explore risk factors contributing to life stress and adversity, and protective factors associated with resilience. The qualitative data will be delineated to propose a typology of older adults living with HIV as characterized by their unmet needs, barriers and facilitators of resilience-building.

Description:

Objectives: The intersection of HIV and ageing has important implications for health and psychosocial wellbeing, which are complex in nature. In a setting with growing number of older adults living with HIV in Hong Kong, as in many other regions in the world, addressing their unmet healthcare needs is paramount. Failure to understand and recognise their needs will impede healthy ageing. This study aims to explore lived experiences of older adults living with HIV in regards their complex needs and resilience-building, with the specific objectives of examining associated factors of resilience development at individual-social- and structural level. Design: A qualitative study targeting 20 older Chinese adults of age 50 or above who are living with HIV who are divided under the following groups: Group A: Chinese men who have sex with men and Group B: Chinese heterosexual males and females Settings: Clinic providing HIV care in the public service Methods: Participants will be recruited through purposive sampling based on their age (50-64; 65 and above of age), gender and sexual orientation. Qualitative, semi-structured interview will be conducted to explore: (1) risk factors contributing to life stress and adversity, and (2) protective factors associated with resilience. Interviews will be digitally recorded, transcribed verbatim and managed using "NVivo" software. Themes will be developed, constantly compared within and between targeted groups, using Grounded Theory approach. Anticipated outcomes: The qualitative data will be delineated to propose a typology of older adults living with HIV as characterized by their (1) unmet needs, (2) barriers of resilience-building, and (3) facilitators of resilience-building.

Recruitment information / eligibility
Status Completed
Enrollment 20
Est. completion date June 10, 2023
Est. primary completion date April 5, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Known and confirmed HIV infection - age of 50 or above - normally living in Hong Kong - permanent residents of Hong Kong - able to communicate in Cantonese Exclusion Criteria: - Active psychiatric disorder - prisoners or under institutionalized care - unable to give consent

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• no intervention
No intervention involved

Locations
Country Name City State
Hong Kong Prince of Wales Hospital Hong Kong

Sponsors (1)
Lead Sponsor Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome
Type Measure Description Time frame Safety issue
Primary risk items risk factors contributing to stress and adversity 1 year
Primary protective factors Factors associated with resilience 1 year
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2